LADENBURG THALM/SH SH Raises United Therapeutics (NASDAQ:UTHR) Price Target to $344.00

United Therapeutics (NASDAQ:UTHR) had its target price boosted by equities research analysts at LADENBURG THALM/SH SH from $319.00 to $344.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. LADENBURG THALM/SH SH’s target price indicates a potential downside of 8.23% from the company’s current price.

A number of other analysts have also issued reports on UTHR. UBS Group boosted their target price on shares of United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a research note on Monday, July 8th. Jefferies Financial Group upped their price target on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. Oppenheimer upped their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday. HC Wainwright boosted their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a report on Thursday. Finally, Wells Fargo & Company boosted their price target on United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research note on Tuesday, August 20th. One research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $366.43.

United Therapeutics Trading Up 3.7 %

NASDAQ:UTHR traded up $13.44 during mid-day trading on Thursday, hitting $374.84. 397,968 shares of the stock traded hands, compared to its average volume of 465,958. The company has a quick ratio of 4.18, a current ratio of 4.35 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $16.63 billion, a price-to-earnings ratio of 17.65, a PEG ratio of 1.27 and a beta of 0.57. United Therapeutics has a 52 week low of $208.62 and a 52 week high of $377.03. The firm’s 50 day moving average is $354.34 and its two-hundred day moving average is $315.28.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. United Therapeutics’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same period last year, the company earned $5.38 EPS. On average, equities research analysts predict that United Therapeutics will post 24.72 earnings per share for the current year.

Insider Buying and Selling at United Therapeutics

In other news, CFO James Edgemond sold 7,782 shares of the business’s stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $366.99, for a total value of $2,855,916.18. Following the sale, the chief financial officer now directly owns 6,426 shares of the company’s stock, valued at approximately $2,358,277.74. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CFO James Edgemond sold 7,782 shares of United Therapeutics stock in a transaction on Monday, October 21st. The stock was sold at an average price of $366.99, for a total value of $2,855,916.18. Following the completion of the sale, the chief financial officer now directly owns 6,426 shares of the company’s stock, valued at approximately $2,358,277.74. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 269 shares of the stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $348.41, for a total value of $93,722.29. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $45,293.30. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 107,012 shares of company stock valued at $36,767,286 over the last 90 days. 12.50% of the stock is owned by insiders.

Institutional Trading of United Therapeutics

Large investors have recently modified their holdings of the stock. ClariVest Asset Management LLC boosted its holdings in shares of United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 42 shares during the period. V Square Quantitative Management LLC purchased a new position in shares of United Therapeutics in the 2nd quarter valued at approximately $30,000. Innealta Capital LLC acquired a new position in shares of United Therapeutics in the second quarter valued at approximately $33,000. USA Financial Formulas acquired a new stake in shares of United Therapeutics during the third quarter worth $33,000. Finally, Values First Advisors Inc. purchased a new position in United Therapeutics in the 3rd quarter valued at $90,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.